Drugs / Drug Resistant Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04165941 | Feb 2020 → Dec 2026 expected | adult glioblastoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drug Resistant Immunotherapy | “The cell therapy that is being used in this study is called gene-modified gamma delta T cells or Drug Resistant Immunotherapy (DRI).” NCT04165941 ↗ |
| Known as | DRI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04165941 ↗ |
| Modality | Cell therapy | “The cell therapy that is being used in this study is called gene-modified gamma delta T cells or Drug Resistant Immunotherapy (DRI).” NCT04165941 ↗ |